Ignite Creation Date:
2024-05-06 @ 7:54 PM
Last Modification Date:
2024-10-26 @ 3:17 PM
Study NCT ID:
NCT06187662
Status:
ENROLLING_BY_INVITATION
Last Update Posted:
2024-01-02
First Post:
2023-12-18
Brief Title:
BrighT STAR LIBRA Leveraging Implementation Science for Blood Culture Reduction Approaches
Sponsor:
Childrens Hospital of Philadelphia
Organization:
Childrens Hospital of Philadelphia
Study Overview
Official Title:
BrighT STAR LIBRA Leveraging Implementation Science for Blood Culture Reduction Approaches
Status:
ENROLLING_BY_INVITATION
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
LIBRA
Brief Summary:
This study will compare two strategies that target distinct determinants of blood culture overuse in an exploratory hybrid pilot trial in 8 PICUs It aims to determine if there is any association between specific strategies used to reduce blood culture overuse on unit-wide blood culture rates patient safety and concurrently explore aspects of the implementation process acceptability feasibility appropriateness
Detailed Description:
Blood cultures are an important test to diagnose bacterial bloodstream infections but can be ordered reflexively excessively and lead to downstream negative patient consequences such as unnecessary antibiotic exposure Work to date has demonstrated safe and effective reduction in blood culture rates in the pediatric intensive care unit PICU setting but optimal strategies to reduce culture use are currently unknown
The primary study team will initially work with all enrolled sites in an identical fashion facilitating a core series of steps for implementing a quality improvement blood culture diagnostic stewardship program which is identical to the steps used in the parent study called BrighT STAR Testing STewardship to reduce Antibiotic use and Resistance In addition the primary study team will randomize sites into two arms in which different strategies are introduced that each target distinct determinants of blood culture overuse The primary study team will examine the impact on blood culture rates as well as evaluate aspects of the implementation process in all sites pre- vs-post intervention
The primary study team will initially work with all enrolled sites in an identical fashion facilitating a core series of steps for implementing a quality improvement blood culture diagnostic stewardship program which is identical to the steps used in the parent study called BrighT STAR Testing STewardship to reduce Antibiotic use and Resistance In addition the primary study team will randomize sites into two arms in which different strategies are introduced that each target distinct determinants of blood culture overuse The primary study team will examine the impact on blood culture rates as well as evaluate aspects of the implementation process in all sites pre- vs-post intervention
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 5K23HL151381-03 | NIH | None | httpsreporternihgovquickSearch5K23HL151381-03 |